Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Steven W Criscione"'
Autor:
Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel L. Karl, Kerrin Mendler, Aleksandra Markovets, Sladjana Gagrica, Oona Delpuech, Jonathan R. Dry, Michael Grondine, Maureen M. Hattersley, Jelena Urosevic, Nicolas Floc’h, Lisa Drew, Yi Yao, Paul D. Smith
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-13 (2022)
Abstract Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patien
Externí odkaz:
https://doaj.org/article/d7852854a3ba43459578c3fb424140e2
Autor:
Derek B Oien, Samanta Sharma, Maureen M. Hattersley, Michelle M. DuPont, Steven W Criscione, Laura B Prickett, Anne U Goeppert, Lisa Drew, Yi Yao, Jingwen Zhang, Ho Man Chan
Publikováno v:
Blood Advances.
B-cell receptor (BCR) signaling is essential for the diffuse large B-cell lymphoma (DLBCL) subtype that originates from activated B-cells (ABC). ABC-DLBCL cells are sensitive to Bruton tyrosine kinase intervention. However, relapsed or refractory ABC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff4345f737f0a4edfc8eae5489d49ba4
https://doi.org/10.1182/bloodadvances.2022009257
https://doi.org/10.1182/bloodadvances.2022009257
Autor:
Lisa Drew, Stephen E. Fawell, Michael Zinda, David M. Weinstock, Raphael Koch, Jamal C. Saeh, Wenlin Shao, Clive S. D'Santos, Chandra Sekhar Reddy Chilamakuri, Valar Nila Roamio Franklin, Nancy Su, Petar Pop-Damkov, Maryann San Martin, Steven W. Criscione, Douglas Ferguson, Theresa Proia, Scott Boiko, Justin Cidado
Intermittent dosing of AZD4573 drives regression of hematological tumor xenografts as predicted by a PK/PD/efficacy model.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4089f363c0de6f76d589e6db02857ef6
https://doi.org/10.1158/1078-0432.22473198.v1
https://doi.org/10.1158/1078-0432.22473198.v1
Autor:
Francis D. Gibbons, Stephen E. Fawell, Barry R. Davies, J. Paul Secrist, Michael Zinda, Martin Wild, Eric Gangl, Ricky W. Johnstone, Andrea Newbold, Gareth P. Gregory, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Alwin Schuller, Nancy Su, Omid Tavana, Areya Tabatabai, Jamal C. Saeh, William McCoull, Edward J. Hennessy, Stephanos Ioannidis, Thomas Gero, R. Bruce Diebold, Jeffrey Varnes, Shannon K. McWeeney, Stephen E. Kurtz, Jeffrey W. Tyner, Tristan Lubinski, Kathleen Burke, Deborah Lawson, Shenghua Wen, Terry Macintyre, Paula Lewis, Ammar Adam, Justin Cidado, Kate F. Byth, Steven W. Criscione, Srividya B. Balachander
Purpose:Targeting Bcl-2 family members upregulated in multiple cancers has emerged as an important area of cancer therapeutics. While venetoclax, a Bcl-2–selective inhibitor, has had success in the clinic, another family member, Bcl-xL, has also em
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8844690ddeffa8863fd595c34c80f01
https://doi.org/10.1158/1078-0432.c.6529392
https://doi.org/10.1158/1078-0432.c.6529392
Autor:
Lisa Drew, Stephen E. Fawell, Michael Zinda, David M. Weinstock, Raphael Koch, Jamal C. Saeh, Wenlin Shao, Clive S. D'Santos, Chandra Sekhar Reddy Chilamakuri, Valar Nila Roamio Franklin, Nancy Su, Petar Pop-Damkov, Maryann San Martin, Steven W. Criscione, Douglas Ferguson, Theresa Proia, Scott Boiko, Justin Cidado
List of antibodies (S1), PK/PD/efficacy model parameters (S2), putative cancer-associated genes (S3), and transcripts modulated by AZD4573 (S4).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9d91db0a50ac30baa8045d2a585387
https://doi.org/10.1158/1078-0432.22473189.v1
https://doi.org/10.1158/1078-0432.22473189.v1
Autor:
Francis D. Gibbons, Stephen E. Fawell, Barry R. Davies, J. Paul Secrist, Michael Zinda, Martin Wild, Eric Gangl, Ricky W. Johnstone, Andrea Newbold, Gareth P. Gregory, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Alwin Schuller, Nancy Su, Omid Tavana, Areya Tabatabai, Jamal C. Saeh, William McCoull, Edward J. Hennessy, Stephanos Ioannidis, Thomas Gero, R. Bruce Diebold, Jeffrey Varnes, Shannon K. McWeeney, Stephen E. Kurtz, Jeffrey W. Tyner, Tristan Lubinski, Kathleen Burke, Deborah Lawson, Shenghua Wen, Terry Macintyre, Paula Lewis, Ammar Adam, Justin Cidado, Kate F. Byth, Steven W. Criscione, Srividya B. Balachander
Figure S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::444106ead769434517a6030981d594b4
https://doi.org/10.1158/1078-0432.22476393.v1
https://doi.org/10.1158/1078-0432.22476393.v1
Autor:
Francis D. Gibbons, Stephen E. Fawell, Barry R. Davies, J. Paul Secrist, Michael Zinda, Martin Wild, Eric Gangl, Ricky W. Johnstone, Andrea Newbold, Gareth P. Gregory, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Alwin Schuller, Nancy Su, Omid Tavana, Areya Tabatabai, Jamal C. Saeh, William McCoull, Edward J. Hennessy, Stephanos Ioannidis, Thomas Gero, R. Bruce Diebold, Jeffrey Varnes, Shannon K. McWeeney, Stephen E. Kurtz, Jeffrey W. Tyner, Tristan Lubinski, Kathleen Burke, Deborah Lawson, Shenghua Wen, Terry Macintyre, Paula Lewis, Ammar Adam, Justin Cidado, Kate F. Byth, Steven W. Criscione, Srividya B. Balachander
contains methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f66d7cdc5a26035ed01be67bc7dad53
https://doi.org/10.1158/1078-0432.22476381.v1
https://doi.org/10.1158/1078-0432.22476381.v1
Autor:
Lisa Drew, Stephen E. Fawell, Michael Zinda, David M. Weinstock, Raphael Koch, Jamal C. Saeh, Wenlin Shao, Clive S. D'Santos, Chandra Sekhar Reddy Chilamakuri, Valar Nila Roamio Franklin, Nancy Su, Petar Pop-Damkov, Maryann San Martin, Steven W. Criscione, Douglas Ferguson, Theresa Proia, Scott Boiko, Justin Cidado
Purpose:Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have progressed clinically but were limited by a narrow therapeutic window. This work des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78a2f9d8bc4116c23d641a6d2430c69
https://doi.org/10.1158/1078-0432.c.6528438
https://doi.org/10.1158/1078-0432.c.6528438
Autor:
Lisa Drew, Stephen E. Fawell, Michael Zinda, David M. Weinstock, Raphael Koch, Jamal C. Saeh, Wenlin Shao, Clive S. D'Santos, Chandra Sekhar Reddy Chilamakuri, Valar Nila Roamio Franklin, Nancy Su, Petar Pop-Damkov, Maryann San Martin, Steven W. Criscione, Douglas Ferguson, Theresa Proia, Scott Boiko, Justin Cidado
Material, methods, supplementary references, and list of supplementary tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452c2d4f2e72a9f64fb946ec7fddeb69
https://doi.org/10.1158/1078-0432.22473192
https://doi.org/10.1158/1078-0432.22473192
Autor:
Eric Pujade-Lauraine, Jessica Brown, Alan Barnicle, Jonathan Wessen, Pierre Lao-Sirieix, Steven W. Criscione, Andreas du Bois, Domenica Lorusso, Ignacio Romero, Edgar Petru, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Magali Provansal, Barbara Schmalfeldt, Sandro Pignata, Cristina Martín Lorente, Dominique Berton, Ingo B. Runnebaum, Isabelle Ray-Coquard
Publikováno v:
JCO Precision Oncology.
PURPOSE The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant progression-free survival (PFS) benefit over placebo plus bevacizumab, particularly in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1b0d08ab959b05bb047fb219cfa5aa
https://doi.org/10.1200/po.22.00258
https://doi.org/10.1200/po.22.00258